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Local or partial unfoldingOcriplasmin, a 249-amino acid recombinant C-terminal fragment of human plasmin, has the potential to de-
grade, within the eye, the protein scaffold that links the vitreous to the retina. This may be beneﬁcial to the
treatment of a number of important ophthalmic indications, such as symptomatic vitreomacular adhesion.
We demonstrate here that ocriplasmin used at therapeutically-relevant concentrations is inactivated in por-
cine vitreous through autolytic degradation. Autolytic cleavage occurs at a limited number of sites, primarily
K156–E157, K166–V167 and R177–V178, which, as predicted, contain a positively-charged arginine or lysine
residue at the P1 position. Our data also suggest that autolytic degradation requires at least local or partial
unfolding of the protein.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The use of plasmin, the enzyme that degrades ﬁbrin polymers, has
been envisioned for human therapy since the 1950s [6]. However, pro-
duction of recombinant plasminogen (the precursor of plasmin) in
eukaryotic systems proved difﬁcult, in part due to the presence of intra-
cellular plasminogen activators [31]. Researchers therefore focused on32 16 751 311.
(M. Vanhove).
-NC-ND license.the production of shorter derivatives of plasminwhich retain ﬁbrinolyt-
ic activity.
Ocriplasmin (des-kringle 1–5 plasmin), also known as microplas-
min, is a truncated form of plasmin. Originally shown to form upon
autolytic degradation of plasmin at high pH, ocriplasmin exhibits in-
tact catalytic activity while lacking all 5 kringle domains [32]. It is
however only in the early 2000s that expression of recombinant
microplasminogen (the inactive zymogen of ocriplasmin) with high
yield in the methylotrophic yeast Pichia pastoris, followed by puriﬁca-
tion, activation with recombinant staphylokinase and formulation as
a stable product [18] allowed the exploration of its therapeutic use.
31F. Aerts et al. / Biophysical Chemistry 165–166 (2012) 30–38Symptomatic vitreomacular adhesion (VMA) is a condition where
age-related posterior vitreous detachment (PVD), i.e. separation of the
posterior hyaloid from the inner limiting membrane, is incomplete.
When this occurs, vitreous traction induces visual distortions (i.e. meta-
morphopsia). VMA can also induce a localized retinal tear or hole (mac-
ular hole) and permanent loss of vision. Vitreous traction can be
relieved through a surgical procedure known as vitrectomy. However,
this procedure carries the risk of damage to the retinal surface or the
optic nerve head [12,29]. Hence, a number of enzymes have been tested
for induction of enzymatic rather that surgical PVD [4,23,27,28]. Among
these, plasmin has been shown to induce PVD in both animal models
[9,14,30] and post-mortem human eyes [10,16], and a similar activity
was demonstrated for ocriplasmin shortly after it became available
[11]. Ocriplasmin is currently under investigation for the intra-ocular
treatment of VMA, and clinical trial data indicate that ocriplasmin is
able to induce posterior vitreous detachment in VMA patients.
In its active form, ocriplasmin (M.W. 27,237 Da) consists of two poly-
peptide chains of 19 and 230 residues linked by two disulﬁde bonds join-
ing residues 6 and 124, and 16 and 24. The 230-residue polypeptide is
further stabilized by 4 intra-chain disulﬁde bonds (Fig. 1). Although stable
in its formulation buffer, it was recognized early that ocriplasmin has lim-
ited stability once injected in the vitreous cavity. In this paper, inactivation
of ocriplasmin in porcine vitreous was characterized from a kinetic and
mechanistic standpoint. We demonstrate here that inactivation of ocri-
plasmin results from autolytic degradation.
2. Materials and methods
2.1. Materials
Porcine eyes were collected at the Rima n.v. slaughterhouse
(Mechelen, Belgium), and transported on ice to the site of experi-
mentation. The vitreous from individual eyes was collected andEW
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Fig. 1. Primary structure of active ocriplasmin.Active ocriplasmin consists of 2 polypeptid
positions of the six disulﬁde bonds are indicated. Lysine 156, lysine 166 and arginine 177 ahomogenized by ﬂushing it twice through a 5 ml syringe and then
three to ﬁve times through a 5 ml syringe capped with a 18 G×1 ½″
needle. The homogenized vitreous was then centrifuged at 4 °C for
5 min at 12,000 g, the supernatant was collected and the pellet dis-
carded. D-Val-Phe-Lys chloromethyl ketone came from Calbiochem
(cat. 627624). Ocriplasmin used in this study was clinical-grade ma-
terial. The recombinant protein was produced in P. pastoris in the
form of the precursor microplasminogen. The protein was recovered
from the fermentation medium and puriﬁed using classical chroma-
tography steps using orthogonal separation modes. Microplasmino-
gen was then activated to the active protease (ocriplasmin) using
an activation resin. Following activation, process impurities were re-
duced by a further chromatography stage. The puriﬁed ocriplasmin
was formulated in formulation buffer, ﬁltered and stored.2.2. Activity measurements
The hydrolytic activity of ocriplasmin was measured using the
chromogenic substrate S-2403 (L-pyroglutamyl-L-phenylalanyl-L-
lysine-p-nitroaniline hydrochloride, Chromogenix, Milano, Italy, cat.
822254-39) by monitoring the initial rate of p-nitroaniline release
at 405 nm. Unless otherwise stated, measurements were performed
at 37 °C in 50 mM Tris–HCl, 38 mM NaCl, 0.01% Tween-80, pH 7.4
with the help of a PowerWave microplate reader (Biotek, KC4 soft-
ware). S-2403 was used at a concentration of 0.3 mM, and the ﬁnal
ocriplasmin concentration in the assay was typically in the 1–10 nM
range.
Residual molar concentrations of active ocriplasmin in vitreous or
neutral-pH buffer were calculated from activity measurements by
comparing the measured activities with the hydrolytic activities de-
termined for reference samples of known concentration. Inactivation
of ocriplasmin in buffer or eye vitreous was measured at 37 °C.E
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re highlighted in red.
Fig. 2. Inactivation of ocriplasmin in porcine vitreous obeys second-order kinetics.
(A) Representative data for the inactivation of ocriplasmin in homogenized porcine vit-
reous. Different doses of ocriplasmin (50, 125, 175 and 250 μg) were added to homog-
enized vitreous recovered from individual porcine eyes, and hydrolytic activity was
measured at various time points. The volume of vitreous was 3.0, 2.5, 2.1 and 2.4 ml
for the 50, 125, 175 and 250 μg doses, respectively. The dotted lines were drawn to
aid visualization. (B) Data from Fig. 2A linearized assuming a second-order reaction,
i.e. by plotting (1/percentage of initial activity) vs. time. The inset shows the natural
logarithm of the percentage of initial activity vs. time. The dotted lines were drawn
to aid visualization. (C) Molar concentrations of active ocriplasmin calculated from hy-
drolytic activity measured at various time points (from the data of Fig. 2A). The dotted
lines represent the best ﬁts with Eq. (1).
32 F. Aerts et al. / Biophysical Chemistry 165–166 (2012) 30–382.3. SDS-PAGE and western-blots
SDS-PAGEwas performed using NuPAGE 4–12% Bis-Tris gels (Invitro-
gen, cat. NP0335BOX), following the manufacturer's recommendations.
The gels were stained using the Simply Blue SafeStain from Invitro-
gen (cat. LC6060). For western-blots, proteins were transferred to
nitrocellulose membranes using the iBlot Gel Transfer device (Invi-
trogen, cat. IB1001EU) and iBlot Gel Transfer Stacks (Invitrogen,
IB3010-02). Following blocking with the Superblock T20 Blocking
Buffer (Thermo Scientiﬁc, cat. 37516), ocriplasmin was detected
using 7H11A11 (1 μg/ml), a murine monoclonal antibody obtained by
immunizing Balb/c mice with recombinant ocriplasmin, followed by
a goat anti-mouse IgG HRP-labeled (Thermo Scientiﬁc, cat. 32430).
HRP activity was revealed using the SuperSignal West Dura chemi-
luminescent substrate (Thermo Scientiﬁc, cat. 34076), combined with
a BioSpectrum imaging system (UVP).
2.4. HPLC
HPLC analyses were performed using an Acquity UPLC instrument
(Waters). The samples were diluted 5-fold in 0.1% triﬂuoroacetic acid
(TFA), 5% acetonitrile, and 6 μl of the diluted samples were injected on
a BEH300 C18 Acquity UPLC column (Waters) pre-equilibrated in 0.1%
TFA, 34% acetonitrile. Elutionwas performedby applying a 34 to 44% ace-
tonitrile, 1.5-ml linear gradient in 0.1% TFA, and the proteins were
detected by following the absorbance at 214 nm. The ﬂow rate was
100 μl/min, and the temperature of the columnwasmaintained at 75 °C.
2.5. N-terminal sequencing
N-terminal sequencing of bands excised from SDS-gels was per-
formed by Eurosequence B.V., Groningen, The Netherlands.
2.6. Mass spectrometry
Autolytic degradation of ocriplasmin (20 μM) was allowed to occur
at 37 °C for 5 h in 25 mM sodium phosphate, pH 7.2, and the reaction
was stopped by the addition of one volume of 0.2 M acetic acid. The
sample was subsequently treated with Tris(2-carboxyethyl) phosphine
hydrochloride (ﬁnal concentration 50 mM) for 1 h at room temperature
to enable reduction of the disulﬁde bridges. Prior to analysis, the sample
was further diluted two times in 50% acetonitrile in HPLC grade water.
Mass spectrometry analysis was performed on an ABI 4800 MALDI
TOF/TOF mass spectrometer running in linear mode with positive ioni-
zation. 4-hydroxy-alpha-cyano-cinnamic acid (5 mg/ml in 50% acetoni-
trile/0.1% triﬂuoroacetic acid) was used as a matrix. Mass range was set
to 5–30 kDa in order to detect both the intact protein and its autolytic
fragments.
3. Results
3.1. Ocriplasmin is rapidly inactivated in homogenized porcine vitreous
in a dose-dependent fashion
Different doses of ocriplasmin (ranging from 50 to 250 μg) were
injected into homogenized vitreous recovered from individual porcine
eyes. Under these conditions, the enzyme was rapidly inactivated
(Fig. 2A). Furthermore, the rate of inactivation increased with the
dose; e.g. the percentage of initial activity decreased from 43±4 to
21±7 after 7 h, and from 29±5 to 8±4 after 24 h for the 50 and
250 μg doses, respectively.
3.2. Inactivation of ocriplasmin in vitreous follows a second-order process
The observation that ocriplasmin loses its activity in a concentration-
dependent manner once diluted in vitreous suggests that inactivation
Fig. 3. Ocriplasmin inactivates in a similar manner in a neutral-pH buffer and in
vitreous.(A) Inactivation of ocriplasmin in neutral-pH buffer (PBS). Different doses of
ocriplasmin (50, 125, 175 and 250 μg) were diluted in PBS, and hydrolytic activity
was measured at various time points. The volume of PBS was 3.0, 2.5, 2.1 and 2.4 ml
for the 50, 125, 175 and 250 μg doses, respectively, in order to match the data obtained
in vitreous (Fig. 2A). The dotted lines were drawn to aid visualization. (B) Data from
Fig. 3A linearized assuming a second-order reaction, i.e. by plotting (1/percentage of
initial activity) vs. time.
33F. Aerts et al. / Biophysical Chemistry 165–166 (2012) 30–38does not occur through a monomolecular (ﬁrst-order) process. This
was conﬁrmed by the non-linearity of the natural logarithm of the activ-
ity vs. time plots. By contrast, the inactivation data could be linearized as-
suming a second-order process, i.e. by plotting (1/percentage of initial
activity) vs. time (Fig. 2B). Therefore, the activities measured at various
time points were converted into molar concentrations and the concen-
tration vs. time curves were analyzed with Eq. (1), which represents a
second-order process (Fig. 2C). Eq. (1) was obtained after rearranging
1/C=1/C0+k.t so that concentration vs. time plots can be directly ana-
lyzed by non-linear regression. This analysis led to a second-order rate
inactivation constant of 81±15 M−1 s−1.
C ¼ C0= 1þ C0:k:tð Þ ð1Þ
In Eq. (1), C0 and C are the molar concentrations of active ocriplas-
min at time 0 and time t, respectively, t is the time (expressed in s)
and k is the second-order rate constant (expressed in M−1 s−1).
3.3. Inactivation of ocriplasmin in neutral-pH buffer and vitreous obeys
similar kinetics
We found that the behavior of ocriplasmin in a neutral-pH buffer
(e.g. PBS) is similar to that observed in vitreous, i.e. inactivation is fast,
concentration-dependent, and obeys second-order kinetics (Fig. 3).
We therefore speculated that ocriplasmin inactivates through an identi-
cal mechanism both in neutral-pH buffer and in vitreous. Inactivation,
however, was found to be somewhat faster in PBS, with a second-
order rate constant of 176±18M−1 s−1.
3.4. Inactivation of ocriplasmin in neutral-pH buffer and vitreous is caused
by autolysis
Autolysis of various proteases (including plasmin) has been
reported to obey second-order kinetics [15,24–26]. Stoner et al. [26]
proposed a two-step model for the autolysis of proteases, where the
ﬁrst step consists of an equilibrium between native (N) and unfolded
(U) protease, while the second involves the cleavage of an unfolded
protease molecule by a native molecule.
N↔U ðReaction1Þ
U þ N→Fragmentsþ N ðReaction2Þ
Stoner et al. indicate that the above model leads to either ﬁrst order
kinetics if the rate of unfolding in Reaction 1 (i.e. the N→U step) is lim-
iting, or to second-order kinetics if the catalytic lysis of the peptide
bonds is limiting. In the latter case, Stoner et al. demonstrate that the
apparent second-order rate constant k is given by Eq. (2), where kcat/
Km is the catalytic efﬁciency of the enzyme towards itself (assuming
Michaelis–Menten kinetics) and Kunfolding is the equilibrium constant
of Reaction 1 in the above model (Kunfolding=[U]/[N]).
k ¼ kcat=Kmð Þ:Kunfolding ð2Þ
We considered the possibility that ocriplasmin's loss of activity
was caused by autolysis both in neutral-pH buffers and in vitreous.
This hypothesis was ﬁrst tested using SDS-PAGE under reducing condi-
tions. Inactivation of ocriplasmin in PBS resulted in the accumulation of
two major degradation fragments of ~17 and ~10 kDa, respectively
(Fig. 4A). These two fragments were not detectable under non-reducing
conditions, indicating that they were linked by one or more disulﬁde
bond(s). Ocriplasmin degradation could also be visualized by western
blot, with the monoclonal antibody 7H11A11 detecting an ~17 kDa frag-
ment (Fig. 4B), and by HPLC with the accumulation of two major species
with elution times in the 9.0–9.5 min range (Fig. 4C). It should be appre-
ciated here that HPLC analysis was performed without reduction of thedisulﬁde bonds, which means that the two species that accumulate over
time in PBS (indicated by the arrows in Fig. 4C) are distinct from the frag-
ments detected by reducing SDS-PAGE. Instead, they represent ~27 kDa
species that differ in the position of the autolytic cleavage site(s). The
shift in the ratio of the two peaks over time also indicates that one species
forms ﬁrst, and is then slowly converted into the other. Importantly, the
kinetics of degradation as assessed by HPLC correlated well with the
loss of activity (Fig. 4D), indicating that cleavage of the peptide chain re-
sults in the formation of an inactive species. Finally, degradation by au-
tolysis was conﬁrmed unambiguously by demonstrating that the
process was prevented by the plasmin inhibitor D-Val-Phe-Lys chloro-
methyl ketone (Fig. 5). The inhibited enzyme exhibited a slightly mod-
iﬁed elution time (Fig. 5C), but no autolytic fragments could be detected
in this sample.
Importantly, we demonstrated, as suggested by the kinetic analysis,
that inactivation of ocriplasmin in porcine vitreous also results from an
autolytic process. Western blot analysis showed the appearance of a
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Fig. 4 (continued).
35F. Aerts et al. / Biophysical Chemistry 165–166 (2012) 30–38degradation fragment which was undistinguishable from the species
generated in PBS, and no degradation was detected in the presence of
D-Val-Phe-Lys chloromethyl ketone (Fig. 6).
3.5. Effect of sucrose on the rate of microplasmin autolysis
If autolysis involves partial unfolding of the protease as suggested by
themodel of Stoner et al., then solutes that increase the thermodynamic
stability of proteins, such as sugars, should lead to a decrease in the
equilibrium concentration of unfolded protease, which in turn should
translate into a decreased rate of autolysis.
We tested this hypothesis using sucrose as a stabilizing agent, as it
has no detectable effect on the intrinsic activity of ocriplasmin in the con-
centration range used here (Fig. 7A). As expected, the rate of ocriplasmin
autolysis decreased signiﬁcantly in the presence of increasing concentra-
tions of sucrose (Fig. 7A), inactivation being ~12 times slower in the
presence of 1 M sucrose. Since Kunfolding in Eq. (2) is related to
ΔG0unfolding, the Gibbs free energy of unfolding [ΔG0unfolding=−RT ln
(Kunfolding)], it is possible to derive Eq. (3), which allows the calculation
of the ΔΔGunfolding, i.e. the increase in ocriplasmin's thermodynamic
stability for a given sucrose concentration. In Eq. (3), kS and k0 are the
rates of autolysismeasured in the presence and absence of sugar, respec-
tively, R is the gas constant and T the temperature. Fig. 7B shows that
ΔΔGunfolding increased linearly with the sucrose concentration, to reach
a value of 1.5 kcal/mol (6.3 kJ/mol) at 1 M sucrose. Similar ﬁndings
weremade usingmannitol as a stabilizing agent, leading to aΔΔGunfolding
value of ~1.3 kcal/mol (5.4 kJ/mol) at a sugar concentration of 1 M.
ΔΔGunfolding ¼−RT ln ks=k0ð Þ ð3Þ
In order to fully validate the reasoning described above, we also de-
cided to verify that the effect of sucrose andmannitol was not due to an
increase in the viscosity of the solution, although this seemed unlikely
since this would indicate that the autolytic process is controlled by dif-
fusion, and the rate of diffusion-controlled reactions, even for macro-
molecules, is orders of magnitude higher than the rate of ocriplasmin
autolysis (109–1010 M−1 s−1 vs. ~200 M−1 s−1, see e.g. [3]). Instead,
as proposed by Stoner and co-workers (see above), it is more likely
that autolysis is limited by the cleavage of the peptide bonds. In orderFig. 4. Inactivation of ocriplasmin in PBS is due to autolysis.Ocriplasmin was diluted in PBS to
and HPLC. (A) Reducing SDS-PAGE (5 μg loaded). Proteins were visualized by Coomassie sta
last lane shows analysis under non-reducing conditions of material obtained after a 30-m
7H11A11 monoclonal antibody. The arrow indicates the ~17 kDa autolytic fragment. (C) HP
are indicated by an arrow. (D) Disappearance of the intact ocriplasmin species in HPLC is cto demonstrate this experimentally, we followed the autolysis of ocri-
plasmin in the presence of benzamidine, a molecule that behaves as a
competitive inhibitor of plasmin, with a reported Ki value of 0.35 mM
for plasmin [17] and 0.3 mM for ocriplasmin (our own data). In essence,
the use of benzamidine allowed us to tune the hydrolytic activity of
ocriplasminwhilemaintaining all other parameters, including viscosity,
unchanged. Not surprisingly, we observed that autolysis of ocriplasmin
was slowed down in the presence of concentrations of benzamidine
(0.3–0.9 mM, i.e. 1–3×Ki) which only partially inhibit ocriplasmin.
This ﬁnding demonstrates unambiguously that autolytic degradation
is limited by the rate of peptide bond cleavage.
3.6. Autolytic cleavage occurs between residues K156–E157, K166–V167
and R177–V178
Autolysis of ocriplasmin leads to the formation of twomajor degrada-
tion fragments as assessed by SDS-PAGE, although micro-heterogeneity
detected by HPLC indicates the existence of more than one autolytic
cleavage site. In order to identify the sites of cleavage, the ~17 kDa and
~10 kDa bands resolved on SDS-gel were collected and submitted to
N-terminal sequencing. The ~17 kDa fragment contained the sequence
Val-Val-Gly-Gly-Xaa-Val (with Xaa unidentiﬁed amino acid), which cor-
responds to the N-terminus of the intact 230-residue polypeptide.
Sequencing of the ~10 kDa fragment yielded Val-Gln-Ser-Thr-Glu-Leu,
with Xaa-Xaa-Asn-Arg-Tyr-Xaa as a minor sequence. The former se-
quence starts at Val178 and the latter at Val167, which indicates a cleav-
age between Lys166 and Val167, and between Arg177 and Val178.
Cleavage at these two positions was conﬁrmed by mass spectrometry,
with the detection of two species of 7720 and 9073 Da, corresponding
to a Val178→C-terminus fragment (expected mass: 7718 Da) and a
Val167→C-terminus fragment (expected mass: 9070 Da), respectively.
Mass spectrometry revealed the presence of a third species of
15,035 Da which can be identiﬁed as a N-terminus of the 230-residue
polypeptide→Lys156 fragment (expectedmass: 15,030 Da), which sug-
gests that autolytic cleavage also occurs between Lys156 and Glu157.
4. Discussion
Ocriplasmin is capable of degrading a variety of structural pro-
teins, such as ﬁbrin clots [8], laminin and ﬁbronectin, with the latter
two proteins localized at the vitreoretinal interface where they are
believed to play a major role in vitreoretinal attachment [5,13]. Ocri-
plasmin was shown in several clinical studies to induce posterior vit-
reous detachment [2,7]. In two recent multicenter, randomized,
placebo-controlled Phase III studies referred to as TG-MV-006 and
TG-MV-007 and designed to evaluate ocriplasmin for the treatment
of symptomatic vitreomacular adhesion, the primary endpoint
(non-surgical resolution of vitreomacular adhesion) was met for
26.5% of the patients vs. 10.1% for the patients who received a placebo
injection (pb0.001, pooled results of the TG-MV-006 and TG-MV-007
trials).
Ocriplasmin is onlymoderately stable when injected in vitreous.We
demonstrate here that inactivation of ocriplasmin in both neutral-pH
buffer and porcine vitreous is exclusively due to autolytic degradation.
The slower inactivation observed in vitreous (k=81M−1 s−1 vs.
176 M−1 s−1 in PBS) might be attributed to the presence of species
which interact with ocriplasmin, which would translate into a higher
Km and a corresponding decrease in the rate of autolysis (Eq. (2)). Alter-
natively, the vitreous may contain solutes that increase ocriplasmin'sa ﬁnal concentration of 18.4 μM, and autolysis was followed by SDS-PAGE, western blot
ining. The arrows indicate the position of the ~17 and ~10 kDa autolytic fragments. The
in incubation. (B) Western blot (1 μg loaded). Ocriplasmin was detected using the
LC (0.6 μg injected). Peaks corresponding to species formed upon autolytic degradation
oncomitant with the loss of activity.
36 F. Aerts et al. / Biophysical Chemistry 165–166 (2012) 30–38thermodynamic stability, thereby leading to the presence of a
lower concentration of the unfolded, autolysis-sensitive species at
equilibrium.
As predicted for an autolytic process, inactivation of ocriplasmin fol-
lows second-order kinetics. Inactivation is therefore concentration-
dependent, with faster inactivation observed at higher doses. Consider-
ing an average volume of vitreous of 4.5 ml for a human eye, a dose of
125 μg per eye as used in the TG-MV-006 and TG-MV-007 trials, and
an autolytic rate constant of 81 M−1 s−1, it is anticipated that the resid-
ual concentration of ocriplasmin will have been reduced to 50% after
~3.5 h and to 10% after ~30 h.
Detectable autolytic cleavage is restricted to only three positions
(K156–E157, K166–V167 and R177–V178). All three cleavage sites
are in agreement with the expected speciﬁcity of ocriplasmin,
known to cleave after positively-charged arginine or lysine residues,
although P4–P3–P2 sequences here differ from the optimal substrate
speciﬁcity determined for plasmin [1], with, in particular, the absence
of an aromatic residue (Trp, Phe or Tyr) at position P2. X-ray struc-
ture [20] reveals that positions 166–167 and 177–178 are localizedFig. 5. Autolysis of ocriplasmin is blocked in the presence of the plasmin inhibitor D-Val-Phe
16 min at 37 °C in 25 mM sodium phosphate, pH 7.2, in the presence and absence of the pla
HPLC. (A) HPLC proﬁle for a control sample kept in low-pH buffer (pH~3.1). (B) HPLC proﬁ
arrows indicate the autolytic species. (C) HPLC proﬁle for the sample obtained in the presein a solvent-accessible loop, which may explain their susceptibility
to autolytic cleavage. By contrast, positions 156–157 are partially bur-
ied and less accessible to solvent, which suggests that autolytic degra-
dation requires at least partial/local unfolding, as predicted by the
model proposed by Stoner et al. The validity and relevance of the lat-
ter model were further validated by looking at the effect of stabilizing
agents (sucrose and mannitol) on the rate of autolysis; not only was
the rate of autolysis signiﬁcantly reduced in the presence of sugar,
but also the ΔΔG of unfolding calculated from these data increased
linearly with the concentration of stabilizing agent, as observed by
others from direct measurements of protein stability [19,21,22].
Despite the existence of 3 cleavage sites, only two major autolytic
species could be detected by HPLC. In addition, the HPLC proﬁle indi-
cates that the two species do not accumulate via parallel pathways,
but instead form through a sequential process where one species ap-
pears ﬁrst and is then converted into the other species. We are cur-
rently attempting to identify the exact nature of these two species
in order to gain insights about the sequence of individual autolytic
events.-Lys chloromethyl ketone.Ocriplasmin (ﬁnal concentration 18.4 μM) was incubated for
smin inhibitor D-Val-Phe-Lys chloromethyl ketone. The samples were then analyzed by
le for the sample obtained in the absence of D-Val-Phe-Lys chloromethyl ketone. The
nce of 1 mM D-Val-Phe-Lys chloromethyl ketone.
Fig. 7. The rate of ocriplasmin autolysis decreases in the presence of sucrose, support-
ing a model where autolysis requires unfolding.(A) Ocriplasmin (14.28 μM) was
allowed to autolyze in the presence of various concentrations of sucrose. At different
timepoints, aliquots were collected and the concentration of active enzyme was calcu-
lated from the measure of residual hydrolytic activity. Second order rate constants for
autolysis were obtained by ﬁtting the data with Eq. (2) (dotted lines). The inset shows
initial rates of S-2403 (0.3 mM) hydrolysis recorded in the absence and presence of 1 M
sucrose. (B) ΔΔGunfolding for individual sucrose concentrations were calculated from
(A) with the help of Eq. (3) and plotted as a function of sucrose concentration. The
inset shows the effect of benzamidin on ocriplasmin autolysis. Ocriplasmin concentra-
tion was 14.7 μM. The dotted lines were drawn to aid visualization. All experiments
were conducted at 37 °C in 25 mM sodium phosphate pH 7.2.
20 kDa 
30 kDa 
40 kDa
Time (min)
0 5  10 20 30   40  60  80
50 kDa 
60 kDa 
80 kDa
100 kDa 
120 kDa 
220 kDa 
Controls
C1    C2  C3
Fig. 6. Autolysis of ocriplasmin also occurs in porcine vitreous.Ocriplasmin (ﬁnal con-
centration 18.4 μM) was added to homogenized porcine vitreous. Twenty-microliter
aliquots were collected after the indicated times, and analyzed by western blot. Detec-
tion of ocriplasmin was achieved using the 7H11A11 monoclonal antibody. Lane C1 is a
control where ocriplasmin was allowed to autolyze for 180 min in PBS. Lane C2 is vit-
reous without addition of ocriplasmin. The sample in lane C3 contained 1 mM D-Val-
Phe-Lys chloromethyl ketone.
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